Itm Isotopen Technologien MÜNchen Aktiengesellschaft, commonly referred to as ITM, is a leading player in the nuclear medicine industry, headquartered in Munich, Germany. Founded in 2004, the company has established itself as a pioneer in the development and production of radiopharmaceuticals, particularly for targeted radionuclide therapy and diagnostic imaging. ITM's core offerings include innovative radioisotopes and radiopharmaceuticals, which are distinguished by their high quality and precision in cancer treatment. With a strong focus on research and development, ITM has achieved significant milestones, including the expansion of its operational reach across Europe and beyond. The company is recognised for its commitment to advancing nuclear medicine, positioning itself as a trusted partner in the healthcare sector.
How does Itm Isotopen Technologien MÜNchen Aktiengesellschaft's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Itm Isotopen Technologien MÜNchen Aktiengesellschaft's score of 5 is lower than 91% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Itm Isotopen Technologien MÜNchen Aktiengesellschaft, headquartered in Germany, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that Itm Isotopen Technologien MÜNchen Aktiengesellschaft may not have established formal commitments to reduce its carbon footprint or engage in climate initiatives at this time. As a result, the company’s climate strategy remains unclear within the context of industry standards and expectations for emissions reporting and reduction.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Itm Isotopen Technologien MÜNchen Aktiengesellschaft has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

